Oral Tofacitinib in Refractory Pediatric Alopecia Areata

This case series examined the effects of oral tofacitinib on 7 pediatric patients with refractory alopecia areata. The study revealed that 5 out of 7 children experienced over 50% improvement in their SALT scores after 8 weeks of treatment, indicating significant hair regrowth. The treatment was well-tolerated with no adverse effects reported. These results suggest that oral tofacitinib is a promising and safe alternative for treating pediatric alopecia areata, though further research is necessary to evaluate long-term safety and efficacy.